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9 Objectives. Global concern around over the counter availability of codeine containing products and risk of misuse,
10 dependence and related harms are evident. A phenomenological study of lived experiences of codeine misuse and
11 dependence was undertaken in Ireland, following the Pharmaceutical Society of Ireland’s 2010 guidelines for restricted
12 supply of non-prescription codeine containing products.
13 Methods. In-depth interviews were conducted with a purposive sample of adult codeine misusers and dependents
14 (n = 21), both actively using, in treatment and in recovery. The narratives were analysed using the Empirical Pheno-
15 menological Psychological ﬁve-stepmethod (Karlsson, 1995). A total of 10 themeswith 82 categories were identiﬁed. Two
16 concepts at a higher level of abstraction above the theme-level emerged during the ﬁnal stage of analysis. The concepts
17 identiﬁed were ‘emotional pain and user self-legitimization of use’ and ‘entrapment into habit-forming and invisible
18 dependent use’. These concepts were reported in different ways by a majority of participants.
19 Results. Findings are presented under the following themes: (1) proﬁle and product preferences; (2) awareness of habit
20 forming use and harm; (3) negotiating pharmacy sales; (4) alternative sourcing routes; (5) the codeine feeling; (6) the daily
21 routine; (7) acute and chronic side effects; (8) social isolation; (9) withdrawal and dependence and (10) help-seeking and
22 treatment experiences.
23 Conclusions. There is a public health and regulatory imperative to develop proactive responses tackling public
24 availability of codeine containing medicines, risk minimisation in consumer self-treatment for pain, enhanced patient
25 awareness of potential for habit forming use and its consequences and continued health professional pharmacovigilence.
26 Received 3 July 2015; Revised 2 October 2015; Accepted 12 November 2015
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28 Introduction
29 Contemporary research highlights global concerns
30 around misuse of prescribed and over the counter
31 codeine as the most commonly consumed opiate
32 (Van Hout et al. 2014). Global demand for codeine
33 preparations has increased by 27% in the previous decade
34 (INCB, 2012). Prescription of codeine for pain relief is
35 increasing in Europe (Fredheim et al. 2009). Misuse of
36 non-prescription codeine containing medicines is
37 increasing, particularly where available in over the
38 counter available combination products (McAvoy et al.
39 2011) amid calls for stronger regulatory responses to
40 tackle over the counter codeine analgesic misuse (Tobin
41 et al. 2013). Quantifying the extent of such misuse centres
42 on varies by country surveillance and methodological
43approaches utilised, and is complicated by public avail-
44ability and the hidden and heterogeneous characteristics
45of codeinemisuse anddependence (UNODC, 2011, 2013).
46Codeine or 3-methylmorphine is a methylated
47morphine derivative occurring naturally with morphine
48in the poppy seed. It is a short acting, weak tomid-range
49opiate and commonly used to manage mild to moderate
50pain in adults as well as for its antitussive and anti-
51diarrheal properties (Tremlett et al. 2010). Recommended
52daily oral dose for adults is between 30 and 60mg every
534 hours and to a maximum of 240mg (Derry et al. 2013).
54Conversion to morphine by endogenous enzymes
55causes altered perceptions and emotional responses to
56pain (Kelly & Madadi, 2012). Administration of codeine
57incurs common opioid-typical side effects, which
58include sedation, euphoria and constipation. Of note
59is that patient responses to codeine and risk of
60intoxication vary due to genetic variations inmetabolism
61(Ingelman-Sundberg et al. 2007; Zhou, 2009).
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62 Codeine has an identiﬁed abuse potential evident in
63 drug administration research (Babalonis et al. 2013),
64 and multiple reportings of case dependence (Sproule
65 et al. 1999; Frei et al. 2010). Tolerance develops on
66 repeated administration of codeine within a relatively
67 short time frame, with increasing doses whether legit-
68 imate (therapeutic) or intoxicating (non-therapeutic)
69 increasing likelihood of neuro-adaptation and depen-
70 dence symptomatology (Dobbin & Tobin, 2008; Nielsen
71 et al. 2010; Reed et al. 2011). Excessive and/or long-term
72 consumption of combination products containing
73 additives (ibuprofen, paracetamol) carries risk of
74 adverse health consequences such as nephro-toxicity,
75 hypokalaemia, gastrointestinal haemorrhage, acute
76 haemorrhagic necrotising pancreatitis and brain
77 damage, often occurring in individuals with no history
78 of substance use disorders or co-morbidity (for a
79 comprehensive review of clinical case presentations see
80 Van Hout et al. 2014). Furthermore, misuse of codeine
81 may be an iatrogenic cause of psychiatric disturbances
82 (Manchia et al. 2013) with paranoid psychosis
83 frequently associated with codeine cough mixture
84 abuse and symptoms of anxiety and depression
85 occurring with long-term use (Romach et al. 1999;
86 Dobbin & Tobin, 2008).
87 Within trajectories of codeine misuse and depen-
88 dence, a wide ranging proﬁle of codeine user exists; for
89 example, the elderly (Roumie & Grifﬁn, 2004; Agaba
90 et al. 2004); youth (Elwood, 2001; Lam & Shek, 2006;
91 Peters et al. 2003, 2007a, 2007b, 2007c; Shek & Lam, 2006,
92 2008; Ford, 2009; Lao et al. 2010; Wilson et al. 2010; Tang
93 et al. 2012; Agnich et al. 2013); parents (Allotey et al.
94 2004); students (Acocella, 2005); pharmacy customers
95 (Sweileh et al. 2004; Albsoul-Younes et al. 2010); drug
96 and psychiatric treatment patients (Agyapong et al.
97 2013); addiction treatment patients (Akram & Roberts,
98 2003; Myers et al. 2003; Yang & Yuan, 2008; Cohen et al.
99 2009; Thekiso & Farren, 2010; Nielsen et al. 2011;
100 Cooper, 2013b) and internet drug forum users (Van
101 Hout, 2015) each with their own motives, patterns and
102 outcomes for use. However, there is a lack of consensus
103 around a deﬁnition of misuse of pharmaceutical opioid
104 narcotics (Barrett et al. 2008; Casati et al. 2012; Cooper,
105 2013a) with broad misuse of pharmaceutical deﬁnitions
106 including incorrect but legitimate use for medical
107 purposes; use outside of acceptable medical guidelines
108 when self-medicating at higher doses and for longer
109 than advised; use for reasons other than for the
110 instructions on the label or the intended purpose;
111 recreational use for intoxication purposes; and where
112 risks and adverse consequences outweigh the beneﬁts
113 (Nielsen et al. 2008; Casati et al. 2012).
114 Prevalence of codeine misuse and dependence is
115 difﬁcult to monitor and quantify, and relies on indica-
116 tors based on surveillance of treatment cases for
117codeine dependence (Pates et al. 2002; Skurtveit et al.
1182011; Roussin et al. 2013). Codeine dependence is
119generally treated in residential detoxiﬁcation
120programmes, with opiate substitution therapy (metha-
121done or buprenorphine) or lofexidine in community
122detoxiﬁcation (Frei et al. 2010; Mattick et al. 2008; Kelly
123& Madadi, 2012). Clinical proﬁles vary, with majority
124representation of those in middle to late age, females,
125poly substance users, alcohol users and those with
126underlying psychiatric conditions (Myers et al. 2003;
127Johansson et al. 2003; Thekiso & Farren, 2010; Robinson
128et al. 2010; Agyapong et al. 2013). Other studies
129report on characteristics of individuals dependent on
130codeine as young, with lower levels of education
131and employment, reporting chronic pain, family
132history of problematic substance use and with greater
133proportions female when compared with other cohorts
134of opiate dependent individuals (Nielsen et al. 2011).
135For those seeking treatment for codeine dependence in
136Australia, primarily older females are reported which
137distinguish from other groups of opiate dependents,
138although this trend is now changing to reﬂect younger
139males (Nielsen et al. 2015).
140Recent formal drug treatment data involving codeine
141misuse and dependence indicates that 1.9% of persons
142in drug treatment in Ireland (personal communication
143from the National Drug Treatment Reporting System)
144reported codeine as a primary or secondary drug of
145abuse in the time period 2008–2012. Irish studies
146suggest that misusers of codeine are more likely to be
147male, older, with co-morbid psychiatric, physical and
148poly substance illness and with a longer drug depen-
149dence history (Cohen et al. 2009; Thekiso & Farren,
1502010). The covert nature of codeine misuse and depen-
151dence with the co-occurrence of serious co-morbidity
152and complexity of cases highlights the need for further
153research within an Irish context (Thekiso & Farren, 2010).
154This is timely given the changes employed by the Irish
155pharmacy regulator (Pharmaceutical Society of Ireland)
156in 2010 to regulate safe supply of non-prescription
157combination products containing codeine and para-
158cetamol, aspirin or ibuprofen for supply only as ‘second
159line’ products for the treatment of pain relief; with
160comprehensive patient advice provided around correct
161use for short-term use (no longer than 3 days and with
162products in-accessible to the public for self-selection).
163Arguably, more stringent regulations for safe supply
164could potentially reduce misuse of codeine medicines
165among psychiatric patients (Agyapong et al. 2013).
166Therefore, the aim of this study is to gain an under-
167standing of individual and collective experiences of
168codeine use, pathways to misuse and dependence and
169experiences of treatment services in Ireland following
170the introduction of such guidelines for the safe supply
171of over the counter codeine-based products.
2 M. C. Van Hout et al.
172 Methods
173 In-depth interviews were conducted with a purposive
174 sample of adult codeine misusers and dependents
175 (n = 21), both actively using, in treatment and in
176 recovery. In order to distinguish between dependent
177 and non-dependent use, participants completed the
178 severity of dependence screener (SDS) (Gossop et al.
179 1995), which is a ﬁve-item questionnaire, with scores of
180 over ﬁve indicating dependence use in the past
181 12 months. Each item addresses the psychological
182 components of dependence, particularly relating to lack
183 of control, preoccupation and anxieties about the drug
184 used. Items are scored along a four-point scale, and
185 aggregated, with a high score indicating a high level of
186 dependence. Nielsen et al. (2010) in their research on
187 codeine dependence in Australia have suggested a SDS
188 cut off of ﬁve has reasonable sensitivity and speciﬁcity
189 in identifying problematic users of codeine containing
190 products.
191 Recruitment was facilitated by selected gatekeepers
192 (specialist medical doctors) within the National
193 Drug Treatment Reporting System. These gatekeepers
194 assisted in the recruitment of individuals in the centres
195 by identifying codeine misusers and dependent
196 patients and providing information on the study to
197 these patients before their participation in the study.
198 All participants received an information sheet and
199 completed a consent form, which was explained
200 verbally by the interviewer before the interview. All
201 participants were assured of conﬁdentiality and
202 anonymity, and that they could withdraw from the
203 study if they so wished. Interviews lasted between
204 30 and 90 minutes and were audio-recorded with
205 permission. Participants’ anonymity was protected
206 by removal of personal identiﬁers (Wilkinson &
207 Thelwall, 2011).
208 Audio-ﬁles were transcribed and transferred to a
209 Word document that was password-protected and
210 analysed in accordance with the Empirical Pheno-
211 menological Psychological (EPP) ﬁve-step method
212 (Karlsson, 1995) (Table 1). This method is underpinned
213 by Husserl’s (1970) phenomenology theory and
214 strongly aligned with Giorgi’s (1997) principles by
215 facilitating the interpretation of meaning of lived
216 phenomena, in this instance the ‘life world’ experience
217 of codeine misuse and dependence. It is an analytic
218 process based on the interpretation of a dialectic
219 understanding of the hermeneutical circle and its
220 dynamic movement between a sense of the whole
221 picture and of its parts in order to achieve an incre-
222 mental understanding of the lived phenomenon
223 (Karlsson, 1995). The EPP method ensures high validity
224 by emphasising an open, non-judgemental and bias
225 free attitude in interpretation of the data and respect of
226the experiential perspectives of the individuals
227(Maxwell, 1992). It aims to explore subjective
228experiences by ‘describing the meaning-structure of a
229psychological phenomenon. This method yields
230descriptive results, which disclose the intentional
231relationship between the subject and the object of
232experience’ (Karlsson, 1995: 78).
233Table 2 illustrates the emergent 10 themes and
23482 categories. During the ﬁnal step in the analysis
235process, two concepts at a higher level of abstraction
236above the theme-level (Table 2) emerged. These
237concepts centred on the interplay between ‘emotional
238pain and user self-legitimization of use’ and ‘entrap-
239ment into habit-forming and invisible dependent use’.
240For example ‘Pain killers are not just for what is written
241on the back of the pack, muscle pain, period pain,
242toothache, migraine, they should add also pain relief
243from anxiety, depression and heartache’. and ‘Codeine
244is my invisible friend It’s a very powerful drug, I never
245expected it to take me where it did, which was the
246highest of highs and the lowest of lows’. All raw data
247were re-read with these two concepts described by a
248majority participants in distinct ways.
Table 1. Empirical Phenomenological Psychological ﬁve-step
method (Karlsson, 1995)
Step 1 The data ﬁle was read three times so as to familiarise,
identify psychological phenomena and achieve an
overview of the codeinemisuse phenomenon in an
unbiased and open manner, and in the absence of
any speciﬁc hypothesis. Theoretical reﬂection was
withheld at this step
Step 2 The text was then divided into smaller meaning
units (MU), without regard to syntax, included
whole paragraphs to single words, and each time a
new meaning, focus or topic was introduced
Step 3 All MUs were subsequently transformed from the
participants wording and restated in order to
present the signiﬁcant and implicit meaning of the
codeine misuse phenomena in objectivised terms.
In order to obtain interpretative validity (Maxwell,
1992), considerable efforts were made to ensure
respect of the participants’ experience
Step 4 The restated MUs were categorised by repeated
consultation with the raw data, scrutinising that
the category itself was maintained, the
understanding of what the phenomenon is
(noema) and how it is expressed (noesis) and by
considering speciﬁc characteristics and similarities
in this codeine misuse phenomena
Step 5 The generated categories were then part of an
abstraction process to create more general and
overarching themes through the patterns identiﬁed
within related categories. A total of 10 themes with
82 categories emerged from the analysis
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Table 2. Themes and categories
Theme Category
Proﬁle and product
preferences
1. Minority prior experience of illicit drugs such as heroin, cannabis, cocaine and ecstasy.
2. Opinions around combining codeine medicines with alcohol and illicit drugs mixed with regard to
desired intoxication outcomes.
3. Codeine combined with alcohol, particularly at night time.
4. Preference for misuse of Nurofen+®, with some displacement during times of unavailability to use of
other codeine containing medicines, both non-prescription and precribed (Solpedeine®, Feminex®,
Solpadol®, Tylex®, Codinex®).
5. Use of prescribed distalgesic containing codeine.
6. The effect of Nurofen+® described as optimal for intoxication.
7. Solpedeine® observed to contain too much caffeine, with unpleasant symptoms on excessive use.
8. Feminex® observed to cause nausea.
9. Consumption of tablets favoured.
Awareness of habit
forming
use and harm
1. Lack of awareness of addictive potential of codeine containing medicines and the harms related to
additives such as ibuprofen and paracetamol.
2. Few read product information leaﬂet.
3. Health professionals (users) aware of additive potential and related harms.
4. Lack of public awareness and televised product marketing as painkiller by companies.
5. Need for greater information provision around use, and risks of misuse from prescribing doctors
relating to codeine containing medicines.
6. Low awareness of intoxication potential of codeine containing medicines for recreational purposes.
7. Consultation of the internet to learn more about which products contained codeine when actively
misusing.
8. Low reporting of tablet splicing of Nurofen+® and cold water extraction.
9. Low reporting of consumption of food before consumption of large amounts of tablets.
10. Despite awareness of habit forming use and harm, while actively misusing, denial and inability
to stop.
Negotiating
pharmacy sales
1. Accessing of pharmacies as primary route to securing codeine containing medicines.
2. Accessing multiple pharmacies in different locations and at intervals in order to circumvent
suspicion.
3. Few purchased over the internet.
4. Awareness of deception and overt manipulation of pharmacy and medical staff.
5. Intense discomfort relating to the thought processes of seeking and securing sufﬁcient supplies of
codeine containing medicines.
6. Awareness of regulation for restricted sale of codeine containing medicines.
7. Use of pre-rehearsed scripts when responding to pharmacist interrogation.
8. Appearances in securing a successful sale varied.
9. Asking for a female speciﬁc codeine containing medicine (Feminex®) sometimes secured a
successful sale.
10. Instances when pharmacy staff recognised the customer, led to purchasing of alternative products or
simply leaving the store.
11. Asking friends to purchase on their behalf.
12. Pharmacist intervention at point of sale triggering thoughts and realisations around misuse.
Alternative
sourcing routes
1. Alternative methods of sourcing codeine containing medicines centred on diversion via prescriber,
street and family routes.
2. Border travel to jurisdictions with less stringent regulations around pharmacy supply (Spain and
Northern Ireland).
3. Accessing surplus codeine containing medicines from friends and family, who did not utilise their
repeat script.
4. Street diversion via purchasing frommedical card patient in receipt of repeat scripts and not utilising
the medicine.
5. Manipulation of doctors for early and repeat prescriptions.
6. Consulting multiple doctors and forging of scripts.
7. Health service work related theft.
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Table 2: (Continued )
Theme Category
The codeine feeling 1. Physical reasons for initial use centred on physical pain (migraine, dental, back, menstrual, joint,
postoperative, child birth).
2. Recognition of appreciation and ‘liking’ the effect of codeine, which contributed to development of
inappropriate ‘misuse’ patterns for other emotive reasons.
3. Low initial use for recreational intoxication purposes.
4. Initial perspectives around the codeine intoxication feeling centred on its euphoric, warm, fuzzy
feeling, pleasurable effect and ability to assist sleep.
5. Use generally occurred privately and at home (to a lesser extent at work).
6. Buffer mechanism or ‘crutch’ in negotiating daily tasks and stressors.
7. Codeine’s capacity to reduce stress and enhance relaxation.
8. Codeine to enhance motivation and conﬁdence within normal daily activity.
9. Development of daily use appeared to cement codeines psychological role in the reduction of and
distancing from depression and anxiety.
10. Legitimised use in serving a perceived therapeutic need and availability in pharmacies appeared to
enhance user solitary and covert habitual use.
11. Despite generally consuming codeine products in private homes, commonly alone, codeine
intoxication assisted with social communication.
12. Low reporting of partner use.
13. On consistent use over time codeine intoxication was described as changing from having a sedative
numbing effect to energising the user.
14. Codeine addiction contributing to depression itself.
The daily routine 1. Daily use progressed within several weeks and grounded in the users’ appreciation of the opiate
effect and rising tolerance.
2. Thought processes around consumption of codeine on awakening.
3. Use characterised by intense craving and need to consume in order to ‘feel normal’ and operate
throughout the day.
4. Maximum daily doses ranging between 24 and 115 tablets/day (e.g. between three and four boxes of
Nurofen+®).
5. High dose daily consumption occurring within 6–12 months.
6. Staggered use of high dose amounts throughout the day.
7. Consciously never exceeding over the recommended daily guidelines for use but misusing products
over the long term.
8. Financial and time related cost in supporting a daily ‘codeine habit’
Acute and chronic side
effects
1. Reported acute side effects centred on opiate urticarial itching, distorted vision and respiratory
depression.
2. Chronic health consequences centred on weight loss, rebound headache, nausea, constipation, liver,
bowel and kidney failure, anaemia, seizures, ulcers and swollen stomach.
3. Symptoms of withdrawal centred on emesis, diarrhoea, sweating, agitation, insomnia, seizures and
cramps.
Social isolation 1. Loss of social support networks due to the isolating and pre-occupating nature of codeine
dependence.
2. Codeine dependence itself negatively impacted on family relationships, contributing to child neglect
and ability to sustain employment.
3. Trauma centring on abuse, loss of children, spouses and family homes.
4. Failed attempts to cease use additionally contributed to family dysfunction.
Withdrawal and
dependence
1. Craving and unpleasant withdrawal symptoms supported continued use.
2. Fears around existing pain conditions underpinned difﬁculties in ceasing use.
3. Consumption of sufﬁcient codeine to keep withdrawals at bay in order to sustain normal social
functioning and employment.
4. Necessity to develop a new daily routine and alternate coping mechanisms underpinned difﬁculties
in self-detoxing.
5. Self-detoxiﬁcation attempts common but unsuccessful, and often resulting in greater amounts
consumed when resuming use.
Codeine use, misuse and dependence 5
279 Results
280 Proﬁle and product preferences
281 A total of 57% (n = 12) of the sample were female and
282 43% (n = 9) male. Participants ranged from 26 to 62
283 years old (mean age = 39) with 71% (n = 15) aged
284 between 30 and 49 years. A total of 52% (n = 11) of
285 participants were unemployed. A total of 15 partici-
286 pants admitted to using codeine within the last
287 12months andwith amajority scored 10 or above (80%,
288 n = 12) in the SDS. A total of 18 of the 20 participants
289 reported codeine-based medications (e.g. Solpadol®,
290 Nurofen Plus® or Solpadeine®) as their primary
291 problematic drug, with the remainder reporting heroin
292 (n = 1) and distalgesic (n = 1) as primary. A total of
293 62% (n = 13) reported Nurofen Plus® was their
294 primary drug of use with 67% (n = 14) of participants
295 reporting that they were currently on methadone
296 maintenance treatment and 14% (n = 3) on Suboxone®.
297 Some participants had prior experience of illicit
298 drugs such as heroin, cannabis, cocaine and ecstasy.
299 Opinions around mixing codeine medicines with
300 alcohol and illicit drugs were mixed with regard to
301 desired intoxication outcomes. Many combined
302 codeine with alcohol, particularly at night time.
303 Every weekend I would combine my codeine use
304 with alcohol and or weed for the extra ‘buzz’.
305 I really likedmisxing the diazepamwith the codeine,
306 it made the high more intense or lasted longer.
307 Displacement to more serious opioids (‘Oxycontin®’
308 and heroin) was reported by two participants.
309The majority of participants reported preference for
310misuse of Nurofen Plus®, with some displacement
311during times of unavailability to use of other codeine
312containing medicines, both over the counter and pre-
313scribed (Solpadeine®, Feminex®, Solpadol®, Tylex®,
314Codinex®). A minority reported use of prescribed
315distalgesic containing codeine.
316I have used them [Solpadeine] as a last resort. If
317I was going to be sick and if I couldn’t get
318Nurofen Plus ®. Just to stop the withdrawal,
319I would take the cough syrup and the Solpadeine.
320The effect of Nurofen Plus® was described by many
321participants as optimal for intoxication purposes.
322Solpadeine® was observed to contain too much
323caffeine, with unpleasant symptoms on excessive
324use while Feminex® was reported to cause nausea.
325Consumption of tablets was favoured.
326Awareness of habit forming use and harm
327The majority of participants were not aware of the
328addictive potential of codeine containing medicines
329and the harms related to additives such as ibuprofen
330and paracetamol. A minority (two) reported reading
331the product information leaﬂet. Two participants were
332health professionals and were aware of addictive
333potential and related harms.
334You were never told. Now you know that it’s not
335the codeine that is the problem, it’s the Ibuprofen
336that is the problem.
Table 2: (Continued )
Theme Category
6. Few sourced street methadone to assist in withdrawals.
Help-seeking and
treatment experiences
1. Help-seeking efforts overall positive and grounded in pharmacist and treatment service intervention.
2. Realisation of being an addict and loss of employment contributed to decisions to attempt
detoxiﬁcation.
3. Barriers to treatment access and retention centred on stigma and labelling as drug addict, particularly
in the case of supervised methadone consumption in pharmacies.
4. Supportive medical care and a slow approach to tapering of codeine products themselves, or
substitution agents to avoid unpleasant withdrawals optimal.
5. Relapse with codeine phosphate tapering universal due to lack of effect on cravings, and instances of
‘topping up’ with Nurofen+®.
6. Difference in effect between prescribed codeine phosphate and Nurofen+® complicated successful
withdrawal attempts.
7. Adopting a new daily routine was deemed important in stabilisation.
8. Suboxone® viewed very positively in removal of craving and withdrawal effects.
9. Integrated pharmacy led detoxiﬁcation can offer an alternative to accessing mainstream drug
treatment centres.
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337 One participant commented on a lack of public
338 awareness and televised product marketing as pain-
339 killer by companies.
340 I really don’t think people know the danger of
341 codeine, but the ads are back on the television now.
342 The majority of participants commented on the need
343 for greater information provision around use, and risks
344 of misuse from prescribing doctors relating to codeine
345 containing medicines.
346 If it was explained to me properly by the doctor
347 what the risks could be, I may not have even gone
348 down that road in the ﬁrst place, the predict-
349 ability and how quickly it would take for you to
350 get addicted on it. I think patients should be told
351 more about what the symptoms are andwhat can
352 happen.
353 Aminority of participants were aware of intoxication
354 potential of codeine containing medicines for recrea-
355 tional purposes, but were unaware of addiction risk.
356 My cousin said that we could get it [codeine]
357 fromNurofen Plus®. At that time we didn’t know
358 it was addictive.
359 Nearly all participants reported consulting the inter-
360 net to learn more about which products contained
361 codeine when actively misusing. In terms of optimising
362 the effect and reduction of harm by removal of additives,
363 two participants reported tablet splicing of Nurofen
364 Plus® and cold water extraction. One reported eating
365 food before consumption of large amounts of tablets.
366 The best part was that the paracetemol would
367 freeze and all the rest of the water was just golden
368 heaven to drink off.
369 Despite becoming aware of habit forming use and
370 harm, while actively misusing, participants described
371 denial and were unable to stop.
372 … to be honest I don’t think it would have chan-
373 ged, I knew what was in them, I knew they were
374 addictive.
375 Negotiating pharmacy sales
376 All reported accessing pharmacies as their primary
377 route to securing codeine containing medicines. All
378 described accessing multiple pharmacies in different
379 locations and at various intervals in order to circum-
380 vent suspicion. One participant described purchasing
381 over the internet.
382 … you would have to travel wider, and just go to
383 pharmacies less frequently. An addiction will
384ﬁnd a way, there’s always a way.When youwant
385something you will always ﬁnd a way to get it.
386Awareness of deception and overt manipulation of
387pharmacy and medical staff was described.
388In my time of addiction, I knew what pharmacist
389was on and in what place and what name/s
390I used last time. Addiction teaches you master
391manipulation. No matter what barriers you build
392an addicts mind goes far beyond it.
393Many described intense discomfort relating to the
394thought processes of seeking and securing sufﬁcient
395supplies of codeine containing medicines.
396I get so worked up that I am going to get them…
397and something pulls me back coz I really don’t
398really want to get them … I’m emotionally
399drained.
400All participants were aware of PSI 2010 regulation
401for restricted sale of codeine containing medicines, and
402employed pre-rehearsed scripts when responding to
403pharmacist interrogation. Opinions around appear-
404ances varied, from ‘looking dishevelled and in pain’ to
405appearing “professional” (particularly relating to
406health professional attire, I would go in there with my
407nurses uniform and they would never refuse.)
408I probably looked like I let go of my appearance,
409I really didn’t care. I got up in the morning and
410the ﬁrst thing on mymindwas where was I going
411to go today to get the codeine.
412Asking for a female speciﬁc codeine containing
413medicine (Feminexs®) sometimes secured a successful
414sale.
415When it was men, I would deliberately embarrass
416them so that I’d get them (Nurofen Plus®), and if
417he tried to make me elaborate, he wasn’t long
418blushing and going behind and getting the box
419for me.
420Instances when pharmacy staff recognised the
421customer, led to purchasing of alternative products or
422simply leaving the store. Some described asking friends
423to purchase on their behalf. Pharmacist intervention at
424point of sale was described by many as triggering
425thoughts and realisations around misuse.
426Alternative sourcing routes
427Alternative methods of sourcing codeine containing
428medicines centred on diversion via prescriber, street
429and family routes. Border travel to jurisdictions with
430less stringent regulations around pharmacy supply was
431reported by two participants (Spain and Northern
432Ireland).
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433 A minority reported accessing surplus codeine
434 containing medicines from friends and family, who did
435 not utilise their repeat script.
436 Easy enough to come by, I know a friend who got
437 boxes andboxes of it, so she never used to take them.
438 One participant described street diversion via
439 purchasing from a medical card patient who was in
440 receipt of repeat scripts and not utilising the medicine.
441 The only place you can get it is from somebody
442 who has a medical card, you can buy it off them.
443 I think they give out medicines too freely on a
444 medical card.
445 The manipulation of doctors for early and repeat
446 prescriptions was described by several participants.
447 After going through a monthly prescription in a
448 week, I decided it was time to manipulate some
449 doctors about the “pain” I was in.
450 Consulting multiple doctors and forging of scripts
451 was described by one participant.
452 This is when I was cunning and had an addictive
453 mind, I would go to different doctors and I would
454 come with everything and all sorts to get them.
455 I would have 5 or 6 doctors at a time and the scripts
456 I would get, I would copy them at least 5 times.
457 Two health professionals described stealing at work
458 when having access to secured storage for medicines.
459 I just thought about codeine all day long. I stole a
460 few from work but soon it was noticed and
461 I never took from work again [nurse].
462 The codeine feeling
463 Physical reasons for initial use centred on physical pain
464 (migraine, dental, back, menstrual, joint, postoperative,
465 child birth). Displacement toward recognition of
466 codeine’s pleasurable effect and administration for
467 emotional distress and as a coping mechanism (in some
468 instances postnatal depression) was reported by a
469 majority.
470 Very quickly it was not enough in the morning to
471 have me ﬂoating, feeling euphoric, and care free
472 really. I was numb and I liked that. Nothing
473 stressedmewhen it worked, codeine ﬁlled a void.
474 Several participants described recognition of appre-
475 ciation and ‘liking’ the effect of codeine, which
476 contributed to development of inappropriate ‘misuse’
477 patterns for other emotive reasons.
478 I wasn’t expecting the high I got but I was very
479 happy with its effects, it felt like the missing piece
480 to my life. I didn’t share my codeine addiction
481with anyone and I truly believe I became an
482addict straight after feeling its effects.
483One participant described initial use for recreational
484intoxication purposes.
485I used to look forward to it throughout the week
486… to treat myself on Friday.
487Initial perspectives around the codeine intoxication
488feeling centred on its euphoric, warm, fuzzy feeling,
489pleasurable effect and ability to assist sleep. Use
490generally occurred privately and at home (to a lesser
491extent at work), and appeared to act as buffer mechan-
492ism or ‘crutch’ in negotiating daily tasks and stressors.
493Back then it was simply for the feeling of the drug
494alone, not for what the drug gave me.
495I wasn’t in any pain, I would take them to make
496me in better form, get through the day, just purely
497for buzz, just to give me a feeling of euphoria.
498Comments emphasised codeine’s capacity to reduce
499stress and enhance relaxation, and enhance motivation
500and conﬁdence within normal daily activity.
501For more of a normal feeling, it gave me that
502sense of de-stressing the body, emotional relief
503from emotional stress.
504Development of daily use appeared to cement
505codeines psychological role in the reduction of and
506distancing from depression and anxiety.
507I had really no treatment [for depression] but
508I was totally dependent on the codeine, codeine
509was my treatment, codeine was my life.
510Legitimised use in serving a perceived therapeutic
511need and availability in pharmacies appeared to
512enhance user solitary and covert habitual use.
513It’s very socially acceptable because nobody
514knows you’re doing it.
515Despite generally consuming codeine products in
516private homes, commonly alone, some participants
517observed how codeine intoxication assisted with social
518communication.
519I wouldn’t be sociable if I didn’t have them in my
520system.
521Two participants described using with a partner.
522We [husband] did do it together but it wasn’t a
523shared thing, it was a need.
524With consistent use over time codeine intoxication
525was described as changing from having a sedative
526numbing effect to energising the user.
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527 The drug itself, started to change, it was no
528 longer giving me a downer; it was giving me a
529 booster. That’s why it has been so hard; it lifts
530 your spirit.
531 Codeine addiction was also viewed by some as
532 contributing to depression itself.
533 It gave me direct depression … from coming off
534 such a euphoric feeling to just living in the
535 real world.
536 The daily routine
537 Daily use for all progressed within several weeks and
538 grounded in the user’s appreciation of the opiate effect
539 and rising tolerance. The majority of participants
540 described thought processes around consumption of
541 codeine on awakening.
542 I took four and I got a little feeling off of them and
543 I liked it, so then I gradually increased to six and
544 then I just kept going up and up, I just kept taking
545 them all the time.
546 It slowly expanded pace really rapidly were I was
547 taking three boxes in the morning. I would get all
548 the usual feelings.
549 Usewas characterised by intense craving and need to
550 consume in order to ‘feel normal’ and operate
551 throughout the day.
552 I was taking 28 tablets a day. I was taking them to
553 feel normal initially and then the more you take
554 the worse you feel, you end up feeling sick from
555 them but yet you couldn’t be without them.
556 Maximum daily doses were reported to range
557 between 24 and 115 tablets/day (e.g. between three
558 and four boxes of Nurofen Plus®) and with high
559 dose daily consumption occurring within 6–12
560 months. Staggered use of high dose amounts
561 throughout the day was common. One participant
562 reported use of 96 tablets of Nurofen Plus® in one go.
563 I’d take 24 at once and then at lunch time take the
564 other 24 and then in the evening then take the
565 other 24 so that was a ritual of things, gradually
566 I had to take more because I’d take 24 and
567 I wouldn’t feel anything.
568 Some reported consciously never exceeding over
569 the recommended daily guidelines for use but misusing
570 products over the long term, and recognising
571 dependence within 3 months.
572 Never took more than eight, always within
573 recommended guidelines, but dependent within
574 three months.
575Participants commented on ﬁnancial and time
576related cost in supporting a daily ‘codeine habit’.
577It’s an expensive little endeavour.
578Acute and chronic side effects
579Reported acute side effects centred on opiate urticarial
580itching, distorted vision and respiratory depression.
581We got really itchy, the blotchy skin and the heat
582ﬂush; the typical Codeine symptoms. As in go to
583sleep and not breath and then wake up. That’s
584why you can’t really take too much. You realise
585you’re so short of breath.
586Chronic health consequences centred on nausea,
587constipation, liver, bowel and kidney failure, anaemia,
588seizures, ulcers and swollen stomach.
589The real physical affect codeine has had on me is
590bowel failure. I now take 3 different types of
591medications for my bowels alone.
592Several participants described loss of appetite and
593weight. Rebound headaches were described by half
594of participants. Symptoms of withdrawal centred
595on emesis, diarrhoea, sweating, agitation, insomnia,
596seizures and cramps.
597I’d get withdrawals, I’d get very, very agitated
598and pains in my legs and my arms and my
599stomach. I’d get blinding head aches and loss of
600appetite, restlessness, couldn’t sleep, I wasn’t
601eating, complete shutdown.
602Social isolation
603Loss of social support networks due to the isolating and
604pre-occupating nature of codeine dependence was
605described by some participants.
606I don’t really have friends any more. My friends
607are gone and it’s more a companion addiction. It
608feels like it has its arm around you. That’s how
609it is for me now. It gives me that sense of security
610and that’s what I’m struggling with at the
611moment, it’s to break that cycle.
612Codeine dependence itself was viewed by many
613as negatively impacting on family relationships,
614contributing to child neglect and ability to sustain
615employment. Trauma centring on abuse, loss of
616children, spouses and family homes were common.
617Failed attempts to cease use additionally contributed
618to family dysfunction.
619My life has become unmanageable, every penny
620I have has gone to this tablets, I’ve lost my job,
621I’ve lost my partner and kids, I had a nice
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622 home, its actually destroyed my life, it’s taken
623 everything, it’s taken away my self-respect.
624 Withdrawal and dependence
625 Craving and unpleasant withdrawal symptoms were
626 described as supporting continued use. Fears around
627 existing pain conditions underpinned difﬁculties in
628 ceasing use for some participants.
629 It causes horrible dependence, physical and
630 mental dependence. It just destroys your life
631 basically.
632 Many tried to consume sufﬁcient codeine to keep
633 withdrawals at bay in order to sustain normal social
634 functioning and employment.
635 I was taking it almost to work because of the
636 withdrawal symptoms. Once I realised I was
637 addicted to something, I realised I’d have to take
638 too much time off work. So it would end up being
639 a vicious circle.
640 The necessity to develop a new daily routine and
641 in many instances alternate coping mechanisms
642 underpinned difﬁculties in self-detoxing.
643 When I used to get up and feel crap, I’ll take it and
644 feel instantly better. Now it has become part of
645 my daily routine in my daily life. Trying to break
646 that is really hard.
647 Self-detoxiﬁcation attempts were common but
648 unsuccessful, and often more excessive in amounts
649 consumed thereafter. One participant described
650 sourcing street methadone to assist in withdrawals.
651 I tried to cut down on it, gradually cut down, and
652 then I’d just have a bad day and I’d be straight
653 back up to 24 [tablets].
654 Help-seeking and treatment experiences
655 Help-seeking efforts were overall positive and
656 grounded in pharmacist and treatment service
657 intervention. Realisation of being an addict and loss of
658 employment was described by several as contributing
659 to decisions to attempt detoxiﬁcation.
660 The person who becomes addicted to pain killers
661 and over the counter drugs wouldn’t necessary
662 see themselves as a drug addict.
663 There is no difference between a heroin addict
664 and some who’s been taking Nurofen Plus®.
665 Because at the end of the day, it’s not the
666 substance they’re treating, it’s the person.
667Barriers to treatment access and retention centred
668on stigma and being labelling as a drug addict,
669particularly in the case of supervised methadone
670consumption in pharmacies.
671It made me feel very shameful and my picture
672was on the wall with methadone, I just felt very
673ashamed.
674Supportive medical care and a slow approach to
675tapering of codeine products themselves or substitution
676agents to avoid unpleasant withdrawals were advised.
677If you are taking four boxes it would take you two
678and a half years to come down. You can’t go
679down too fast, the body needs time to catch up.
680For a minority of participants with experience (all
681unsuccessful) of codeine phosphate withdrawal, the
682sedative effect of codeine phosphate tapering treatment
683form contrastedwith theNurofen Plus® energising effect,
684which patients found complicated their successful detox.
685There is a huge difference. The over the counter
686codeine phosphate makes you feel down and
687sleepy, Nurofen Plus® makes you the opposite,
688gives you uplift.
689Relapse with codeine phosphate tapering was
690universal due to lack of effect on cravings, and instan-
691ces of ‘topping up’ with Nurofen Plus®.
692I wouldn’t even say I lasted a day or two on that.
693I felt a huge overwhelming need, even when
694I was taking them [codeine phosphate].
695Particularly for those on methadone, while mana-
696ging unpleasant withdrawals, adopting a new daily
697routine was deemed important.
698I realised that routine is very important in my
699addiction, so I had to start my own new routines.
700Suboxone® in particular was viewed very positively
701in removal of craving and withdrawal effects.
702From the very ﬁrst day I put a Suboxone in my
703body, I have no jitter, I have no side effects,
704I never ever took a codeine since the ﬁrst day
705I took Suboxone.
706It was a miracle, a door was opened for me, I was
707able to function, I was on no codeine. I actually
708walked into the chemist and I apologized to
709everyone who I had fooled.
710Some participants suggested that the pharmacist
711could support them in tapering down from over the
712counter codeine containing products, as an alternative
713to accessing mainstream drug treatment centres.
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714 I think they would appreciate a different
715 approach, if there was in the middle place where
716 people using over the counter drug could go,
717 instead of going to the main drug centres.
718 Discussion
719 This study presents unique qualitative insights around
720 codeine misuse and dependence within an Irish context
721 following the PSI’s regulatory restrictions in 2010 to
722 promote safe supply of non-prescription codeine
723 containing products in Ireland. ‘Trustworthiness’ of
724 the data (Lincoln & Guba, 1985) is promoted by
725 veriﬁcation of extensive similarities across the lived
726 experience of participants, along with horizontal and
727 vertical consistency in the interpretation of the data,
728 and partial phenomenological psychological reduction
729 (Karlsson, 1995).
730 The study builds on ﬁndings reported in earlier
731 qualitative studies with codeine dependents in the
732 United Kingdom (Cooper, 2011, 2013a), Australia
733 (Nielsen et al. 2010, 2011, 2013) and active online drug
734 users (Van Hout, 2015). Given the covert nature of this
735 issue, confounded by withdrawals, emotional distress
736 and potential for serious co-morbidity, this study
737 presents novel and meaningful illustration of the
738 codeine misuse phenomenon, particularly within the
739 Irish context. Multiple routes to access centred on
740 the easy availability of codeine-based products within
741 pharmacies, when prescribed via repeat or through the
742 forging of scripts, over the counter and diversionary
743 means. All contributed to the misuse of codeine in
744 individuals largely unaware of potential for habit
745 forming use, craving and withdrawals. Two way
746 displacements between prescribed codeine for physical
747 pain management and over the counter sourcing were
748 observed and similar to that illustrated in Cooper’s
749 study in the United Kingdom (2013a). Similar to extant
750 research (Inciardi et al. 2009, 2010; Wilsey et al. 2010;
751 Hamer et al. 2013) online sourcing of codeine rarely
752 occurred in preference for pharmacies, and prescribers.
753 This study supports the distinction of three
754 broad categories of codeine misuse identiﬁed in
755 Australia (Nielsen et al. 2010) and the United Kingdom
756 (Cooper, 2011): (1) use which never exceeds the
757 maximum recommended dose, but in terms of duration
758 and nature of use meets criteria for dependence,
759 (2) consumption of slightly higher than the recom-
760 mended dose (for therapeutic or non-therapeutic
761 reasons) and (3) consumption of doses which sub-
762 stantially exceed recommended doses (generally in the
763 context of serious opioid dependence). Daily doses
764 were described as over the recommended daily dose of
765 240mg, and higher than other studies reporting ranges
766of 21–65 tablets daily (Brands et al. 2004; McAvoy et al.
7672011; VanHout, 2015). Adverse health consequences on
768sustained long-term codeine use were similar to those
769reported earlier in the literature, with withdrawal-
770based medication overuse headache (Katsarava &
771Jensen, 2007; Bendtsen et al. 2012) common.
772The phenomenon of codeine misuse appeared
773closely situated within the ‘blurring’ of therapeutic
774self-medication for legitimate medical reasons (chronic
775pain), and misuse for iatrogenic dependence (Sproule
776et al. 1999; Nielsen et al. 2010; Hamer et al. 2013; Roussin
777et al. 2013; Nielsen et al. 2014), alongside individual
778difﬁculties in self-identifying problematic use along
779their own trajectory of use (Pates et al. 2002; Nielsen
780et al. 2010). Of note were the invisible and covert
781characteristics of dependent use, combined with social
782isolation over time. Use of codeine products was
783described as facilitating the individuals’ capacity to
784operate quasi-normally within life and work stressors
785and relationships. The research supports that indivi-
786duals dependent on codeine largely differ from other
787population’s dependent on prescription opioids by
788higher employment rates (Nielsen et al. 2011, 2014).
789Recognition of needing help for codeine dependence or
790identiﬁcation as ‘drug addict’ (Dobbin & Tobin, 2008;
791Nielsen et al. 2010; Cooper, 2013a, 2013b) occurred
792when adverse effects and socio-economic problems
793relating to codeine misuse became intolerable. Help
794seeking was positive, despite some reporting of stigma
795relating to methadone maintenance treatment. Use of
796Suboxone (buprenorphine and naloxone) showed
797promise in stabilisation and recovery.
798Conclusion
799This study highlights the unique and hidden nature of
800the codeine misuse phenomenon and with trajectories
801of habit forming use and dependence particularly
802underpinned by presence of emotional distress and
803self-medication. Interventions for referral, treatment
804and management of codeine misuse remain limited
805given it’s heterogeneous nature, over the counter
806availability and lack speciﬁcity for this distinct group of
807opiate dependents despite extrapolation from extant
808evidence-based opioid policies and protocols (Myers
809et al. 2003; Thekiso & Farren, 2010; Cooper, 2011, 2013a;
810Reed et al. 2011). Access to existing treatment systems
811is hampered by stigma and poor consideration of
812needs, with pathways and outcomes complicated by
813requirements for the co-existing management of
814physical pain (Dobbin & Tobin, 2008; Fishbain et al.
8152008; Reed et al. 2011). There is a public health and
816regulatory imperative to develop proactive responses
817tackling public availability of codeine containing
818medicines, risk minimisation in consumer self-
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819 treatment for physical and emotional pain, need for
820 enhanced patient awareness of habit forming use and
821 its consequences, and continued health professional
822 screening and pharmacovigilence (Casati et al. 2012;
823 Cooper, 2013b; Agnich et al. 2013; Van Hout et al. 2014).
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